news.med.miami.edu
Jun 16, 2025, 02:06
C. Ola Landgren: Presenting ADVANCE Trial Results in Multiple Myeloma at EHA25
C. Ola Landgren, Leader, Translational and Clinical Oncology Program/Experimental Therapeutics at Sylvester Comprehensive Cancer Center, shared a post on LinkedIn:
“Thank you, EHA25, for inviting me to present our results from the randomized, multicenter ADVANCE clinical trial for the treatment of patients with newly diagnosed multiple myeloma – at the annual meeting in Milan, Italy!
The study shows that the 4-drug combination with Daratumumab-Carfilzomib-Lenalidomide-dexamethasone (Dara-KRd) delivers significantly (p<0.0001; OR=2.9) higher MRD negativity rates compared to KRd. The results are consistent across subgroups.
The progression-free survival analysis shows that at almost 3 years of follow-up, 92% of the patients treated with Dara-KRd) are are doing well and are free from progression. The study was open for enrollment, independent of transplant eligibility (transplant eligible, transplant ineligible, and transplant deferred). MRD negativity after 8 cycles of combination therapy was the primary endpoint. There were no new safety signals.
We conclude that Dara-KRd is a new standard of care for newly diagnosed multiple myeloma patients, independent of transplant eligibility.
Thank you to all patients and family who participated in the ADVANCE clinical trial for newly diagnosed multiple myeloma! Thank you to all our collaborators and thank you to our funding support!”
More posts from EHA 2025.
-
Aug 13, 2025, 09:21VELORA Discover Study Now Enrolling: Advancing Care for Type 1 Von Willebrand Disease
-
Aug 13, 2025, 06:44Chokri Ben Lamine: Causes and Diagnostic Approach to PTT Prolongation
-
Aug 13, 2025, 05:41ISTH 2025 Recorded Sessions Now Available on ISTH Academy
-
Aug 13, 2025, 01:39Radoslaw Kaczmarek: Challenges Limiting Gene Therapy Use in Hemophilia
-
Aug 12, 2025, 20:03David McIntosh Urges WHO, the European Blood Alliance, the International Plasma and Fractionation Association to Stop Opposition to VRCD
-
Aug 13, 2025, 16:24Giuseppe Lippi on Laboratory Diagnostics for Immediate Management of Acute Bleeding
-
Aug 13, 2025, 06:13Pip Nicolson: Understanding VITT From COVID-19 Vaccines
-
Aug 13, 2025, 05:23Baseline Hemoglobin Predicts Outcomes in Acute VTE: Low Hb Linked to Higher Bleeding, Ischemia and Mortality Risk
-
Aug 13, 2025, 04:13Lindsey George on Gene Therapy Transforming Hemophilia Care
-
Aug 13, 2025, 02:26Case Report Alert: Basilar Artery Occlusion in IgA-APS
-
Jul 28, 2025, 14:55HORIBA Decoding High Efficiency in Hematology Lab: Free Online Workshop
-
Jul 26, 2025, 17:56HIPEITHO Trial Achieves Remarkable Enrollment Milestone Across 72 Sites in the US and Europe
-
Jul 16, 2025, 15:04Toward Hemophilia Gene Therapy for All? Insights from Prof. Flora Peyvandi in Blood Advances
-
Jul 14, 2025, 16:39Dr. Philipp Bücke: MRI Proven as No.1 Choice for Accurate TIA Diagnosis
-
Jul 13, 2025, 16:05EMA and HMA Mark a Key Step with 1st AI Observatory Report
-
Aug 13, 2025, 15:50Will Parsons Honors National Leaders in Hematology: Drs. Fasipe, Powers and Tubman
-
Aug 13, 2025, 10:25Joshua Muia on His HTRS Leadership Role Impact
-
Aug 11, 2025, 05:16Andreas Calatzis: Any Information on Soviet Thrombelastographs?
-
Aug 9, 2025, 15:36NBCA: Blood Clot Survivor Runs 2025 NYC Marathon with Team Stop the Clot
-
Aug 8, 2025, 18:33Hemophilia Alliance during Tennessee Hemophilia and Bleeding Disorders Foundation Annual Meeting 2025
Aug 13, 2025, 10:25
Aug 13, 2025, 09:44
Aug 13, 2025, 07:58
Aug 13, 2025, 06:44
Aug 13, 2025, 06:13
Aug 13, 2025, 05:41
Aug 13, 2025, 04:13